{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:58:53Z","timestamp":1785560333306,"version":"3.56.0"},"reference-count":33,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330008"],"award-info":[{"award-number":["82330008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82330008"],"award-info":[{"award-number":["82330008"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Medical Innovation Center","award":["CXZX202201"],"award-info":[{"award-number":["CXZX202201"]}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Multiple myeloma (MM) is a malignant plasma cell disorder associated with substantial mortality and long-term disability. With rapid population aging in China, its disease burden may be increasing, yet comprehensive long-term assessments remain limited. Methods: Using data from the Global Burden of Disease Study 2023, we evaluated trends in prevalence, incidence, deaths, and disability-adjusted life years (DALYs) of MM in China from 1990 to 2023. Age-standardized rates were analyzed using Joinpoint regression to estimate temporal trends. Results: Between 1990 and 2023, prevalence, incidence, deaths, and DALYs of MM increased markedly in China, with consistent upward trends in age-standardized rates. The burden was concentrated among older adults and was higher in males than females. Decomposition analysis showed that epidemiological changes were the primary driver of increased DALYs and deaths. Forecasting analyses suggest that although age-standardized mortality and DALY rates may gradually decline, the absolute number of deaths is expected to continue rising. Conclusions: The burden of MM in China has increased substantially over the past three decades and is projected to remain high. Strengthening early detection, risk-oriented prevention, and long-term management strategies is essential to mitigate future disease burden.<\/jats:p>","DOI":"10.3390\/cancers18152449","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:09:42Z","timestamp":1785398982000},"page":"2449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023"],"prefix":"10.3390","volume":"18","author":[{"given":"Huiwen","family":"Liu","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazi","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Su, Q., Yu, J., and Sun, X. (2025). Long-term trends in the burden of multiple myeloma in China: A Joinpoint regression and age-period-cohort analysis based on GBD 2021. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1554485"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","article-title":"The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050","volume":"611","author":"Dou","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102168","DOI":"10.1016\/j.canep.2022.102168","article-title":"Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China","volume":"78","author":"Gao","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Laval, V., Lumbreras-Fern\u00e1ndez, B., Aguado-Bueno, B., and G\u00f3mez-Le\u00f3n, N. (2024). Imaging of Multiple Myeloma: Present and Future. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010264"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-021-01514-0","article-title":"Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma","volume":"81","author":"Elnair","year":"2021","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e010064","DOI":"10.1136\/jitc-2024-010064","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: A meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","first-page":"127","article-title":"Current status of drug development for patients with multiple myeloma: A review of comparison in China and the rest of world","volume":"6","author":"Huang","year":"2023","journal-title":"Antib. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9604","DOI":"10.1002\/cam4.5737","article-title":"The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15\u2009years\u2019 experience of 1256 patients in a national medical center","volume":"12","author":"Yang","year":"2023","journal-title":"Cancer Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(25)01637-X","article-title":"Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Hay","year":"2025","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2352-4642(25)00303-7","article-title":"Quantifying the fatal and non-fatal burden of disease associated with child growth failure, 2000\u20132023: A systematic analysis from the Global Burden of Disease Study 2023","volume":"10","author":"Arndt","year":"2026","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(25)02503-6","article-title":"Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023","volume":"407","author":"Karikalan","year":"2026","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Diao, X., Ben, T., Cheng, S., Niu, S., Gao, L., and Xia, N. (2025). Global, regional, and national multiple myeloma burden from 1990 to 2021: A systematic analysis for of the Global Burden of Disease Study 2021. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-22240-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/07357907.2025.2573084","article-title":"Epidemiological Trends and Disease Burden of Multiple Myeloma in the Middle-Aged and Elderly Population: A Global Study from 1990 to 2021","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Investig."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lv, L., Gao, W., Fan, D., Ma, C., Yan, B., Li, G., and Jiang, Y. (2025). Health inequality and the global burden of mesothelioma: Insights from the global burden of disease study 2021. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14590-2"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Brauer","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ma, C., Yan, B., Li, G., and Jiang, Y. (2025). Global, regional, and national burden of gastric cancer attributable to diet high in sodium from 1990 to 2021. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1674979"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Chen, J., Li, Z., Li, Y., Xie, L., Sasmita, B.R., Luo, S., Huang, B., and Lip, G.Y.H. (2026). Global drivers of heart failure attributable to atrial fibrillation\/flutter: Insights from Joinpoint regression, age-period-cohort analysis, and future projections from the GBD 2021 Study. BMC Med., 24.","DOI":"10.1186\/s12916-026-04628-y"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ma, C., Yan, B., Li, G., and Jiang, Y. (2026). Global, regional and national burden of colorectal cancer attributable to low-fiber diet from 1990 to 2021: A systematic analysis of the global burden of disease study 2021. Front. Nutr., 13.","DOI":"10.3389\/fnut.2026.1688108"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6084012","DOI":"10.1155\/2019\/6084012","article-title":"Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets","volume":"2019","author":"Nishida","year":"2019","journal-title":"J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41598-024-83630-x","article-title":"A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast","volume":"15","author":"Hou","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1097\/CM9.0000000000002600","article-title":"Burden of multiple myeloma in China: An analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019","volume":"136","author":"Liu","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.canep.2024.102537","article-title":"Multiple myeloma incidence, mortality, and survival differences at the intersection of sex, age, and race\/ethnicity: A comparison between Puerto Rico and the United States SEER population","volume":"89","author":"Epstein","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e70192","DOI":"10.1002\/cncr.70192","article-title":"Sex differences in the clinical presentation of patients with newly diagnosed multiple myeloma","volume":"132","author":"Ong","year":"2026","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/ejh.13597","article-title":"Comorbidities in multiple myeloma and implications on survival: A population-based study","volume":"106","author":"Thorsteinsdottir","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/jha2.337","article-title":"Alcohol and tobacco use and risk of multiple myeloma: A case-control study","volume":"3","author":"Cheah","year":"2022","journal-title":"eJHaem"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e052759","DOI":"10.1136\/bmjopen-2021-052759","article-title":"Clinical features and diagnosis of multiple myeloma: A population-based cohort study in primary care","volume":"11","author":"Seesaghur","year":"2021","journal-title":"BMJ Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1097\/JS9.0000000000003949","article-title":"Global burden of multiple myeloma in older adults from 1990 to 2021 and modeled projection to 2050","volume":"112","author":"Hu","year":"2026","journal-title":"Int. J. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Xu, J., Shu, M., Chung, H., Cui, J., Liu, Y., Yan, W., Bai, Q., Dai, N., Li, L., and Zhou, J. (2025). Two Decades of Real-World Study in Newly Diagnosed Multiple Myeloma: Evolving Treatment and Outcomes in China with Reference to the United States. Cancers, 18.","DOI":"10.3390\/cancers18010053"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e47332","DOI":"10.1097\/MD.0000000000047332","article-title":"Changes in the diagnosis, treatment, and prognosis of multiple myeloma in southern Jiangxi Province from 2012 to 2022","volume":"105","author":"Xiao","year":"2026","journal-title":"Medicine"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:19:27Z","timestamp":1785557967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":33,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152449"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152449","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}